chevron_leftBack
As of 16 June 2026, Fennec Pharmaceuticals Inc. has a market cap of $216.16M USD, ranking #20583 globally and #3376 in the United States.
It ranks #1847 in the Healthcare sector, and #358 in the Biotechnology industry.
Key Stats
Market Cap
$216.16MUSD
Enterprise Value
$177.99MUSD
Revenue (TTM)
$44.64MUSD
EBITDA (TTM)
-$6.18MUSD
Net Income (TTM)
-$9.74MUSD
EBITDA Margin
-14%
Profit Margin
-22%
Forward PE
50.6
PS Ratio
4.8
PB Ratio
6.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jeffrey Hackman
open_in_new
Employees
35
Founded
1996
IPO
05 Jun 2001
Website
fennecpharma.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.4% | -6.1% | 6.1% | -16% | -28% | 4.3% |
News
Loading...
FENC Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
FENC
Fennec Pharmaceuticals Inc
ISIN: CA31447P1009
Shares Out.:
Shares Outstanding:
34.737M1
Shares Float:
29.696M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
6.27 USD | |
|
FRX
Fennec Pharmaceuticals Inc
ISIN: CA31447P1009
|
8.52 CAD | |
|
FRX
Fennec Pharmaceuticals Inc
ISIN: CA31447P1009
|
13.78 CAD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
84K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
74K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
13K%
|
-
|
|
NYSE: IQV
|
$26.3B
12K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
11K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
8K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.99B
22K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$45.02B
21K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.64B
20K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.46B
20K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.23B
13K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
12K%
|
-
|
chevron_leftBack